General Catalyst leads funding round joined by .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation to bolster insurance-based mental health program availability in new markets.
General Catalyst leads funding round joined by .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation to bolster insurance-based mental health program availability in new markets.
InStride Health, a specialty pediatric anxiety and OCD treatment provider, released its first annual outcomes report. Based on treatment of over 350 patients, InStride Health demonstrated clinically meaningful results of its coordinated care model.
InStride Health, technology-enhanced mental health treatment for children and adolescents struggling with moderate to severe anxiety and OCD, announces its formal launch. Working in collaboration with McLean Hospital—America’s top-ranked psychiatric hospital and an affiliate of Harvard Medical School.
Privacy Policy | Children & Privacy Policy | HIPAA | Terms of Service
The clinical services offered through this website are provided by InStride Health MA, P.C., doing business in New York as “In Stride Medical,” and InStride Health NJ, P.C., each an independent, physician-owned medical group. For more information about the relationship between InStride Health, Inc., InStride Health MA, P.C., and InStride Health NJ, P.C., click here.
© InStride Health. All rights reserved.
Start the application process here.
